Search Results

The Gmate® VOICE Blood Glucose Monitoring System is intended for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, hand, upper arm, forearm, calf or thigh as an aid in monitoring the effectiveness of diabetes management in the home by individuals with diabetes. The Gmate® VOICE Blood Glucose Monitoring System is intended to be used by a single user and should not be shared with any other person.

The Gmate® VOICE Blood Glucose Monitoring System is for self-testing outside the body (in vitro diagnostic use only) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The Gmate® VOICE Blood Glucose Monitoring System should not be used for the diagnosis or screening of diabetes or for neonatal use. Alternative site testing should be done only during steady-state times (when glucose is not changing rapidly).

The Gmate® VOICE Blood Glucose Monitoring System includes a speaking feature that provides audible test results for diabetic users.

The Gmate® Blood Glucose Test Strips are for use with the Gmate® VOICE Meter for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, hand, upper arm, forearm, calf or thigh.

The Gmate® Control Solution is for use with the Gmate® VOICE Blood Glucose Monitoring System and is intended as a quality control measure to verify the accuracy of your blood glucose test results and to ensure that the Gmate® VOICE meter and Gmate® Test Strips are working properly. The Gmate® Control Solution is intended for use by people with diabetes at home.

The Gmate® VOICE Blood Glucose Monitoring System is an in vitro diagnostic device designed for measuring the concentration of glucose in whole blood, which is used with the Gmate® Blood Glucose Test Strips.

The test principle is:

This device is an in vitro diagnostic product intended for the measurement of glucose concentration in human blood. The principle of the test relies upon a specific type of glucose in the blood sample, the glucose oxidase that reacts to electrodes in the test strip. The test strip employs an electrochemical signal generating an electrical current that will stimulate a chemical reaction. This reaction is measured by the Meter and displayed as your blood glucose result.

This document is a 510(k) summary for the Gmate® VOICE Blood Glucose Monitoring System, which primarily focuses on establishing substantial equivalence to a predicate device rather than detailing specific clinical study results against acceptance criteria. Therefore, much of the requested information regarding acceptance criteria and study particulars for a medical AI device is not present. However, I can extract the available relevant information and highlight the missing details based on the context of a 510(k) submission.

Missing Information:
This document is a 510(k) summary for a blood glucose monitoring system, not specifically an AI-powered diagnostic device in the modern sense. Consequently, several of the requested categories are not applicable or not detailed in this type of regulatory submission. Specifically, there is no mention of "AI" or "machine learning," and therefore no information on:

• Multi-reader multi-case (MRMC) comparative effectiveness study
• Effect size of human readers with vs. without AI assistance
• Standalone algorithm performance
• Training set sample size
• How ground truth for the training set was established

1. A table of acceptance criteria and the reported device performance

The document does not explicitly state "acceptance criteria" in the format typically seen for an AI diagnostic device. However, regulatory submissions like this often implicitly adhere to performance benchmarks for blood glucose meters. The study described is an "accuracy study" that aims to compare the device's performance against a reference method and implicitly against established standards for blood glucose meters.

2. Sample size used for the test set and the data provenance (e.g., country of origin of the data, retrospective or prospective)

• Sample Size for Test Set: Not specified in this 510(k) summary.
• Data Provenance: Not specified in this 510(k) summary. The company has offices in New York and Seoul, but the origin of the study data is not stated. The studies would typically be prospective to evaluate a new device.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g., radiologist with 10 years of experience)

This is not applicable as the device measures blood glucose which is typically compared against a laboratory reference method, not expert-established ground truth.

4. Adjudication method (e.g., 2+1, 3+1, none) for the test set

Not applicable for a blood glucose monitoring system that compares readings to a reference lab method.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This is a blood glucose meter, not an AI-assisted diagnostic tool requiring human reader interpretation. No AI component is mentioned.

6. If a standalone (i.e., algorithm only without human-in-the loop performance) was done

This device operates as a standalone blood glucose meter. The "algorithm" is the electrochemical detection and glucose concentration calculation. The performance described in the underlying studies (not detailed in this document) would be of the device in its entirety without human-in-the-loop performance modifications, other than the user performing the test.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

For blood glucose monitoring systems, the ground truth is typically established by laboratory reference methods (e.g., YSI glucose analyzer) which are considered highly accurate and precise.

8. The sample size for the training set

Not applicable or not specified. This is a traditional medical device, not an AI model requiring a distinct "training set" in the machine learning sense. The device is calibrated and validated through internal testing before market submission.

9. How the ground truth for the training set was established

Not applicable or not specified, for the same reasons as #8. Ground truth for calibration and validation would be established via highly accurate laboratory reference methods.

Ask a specific question about this device

iHealth BG3 Smart Gluco-Monitoring System is intended to be used for:
· quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertip, palm, forearm, upper arm, calf or thigh
· single person measurement only and should not be shared
• self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control
The iHealth BG3 Smart Gluco-Monitoring System should not be used for the diagnosis of or screening for diabetes, or for neonatal use.
Alternative Site Testing (AST) should be done only during steady state times when glucose levels are not changing rapidly.
The AGS10001 test strips are intended for use with the iHealth BG3 meter to quantitatively measure glucose in fresh capillary whole blood samples drawn from the fingertips, palm, forearm, upper arm, calf or thigh using the iHealthBG3 meter

iHealth BG3 Smart Gluco-Monitoring System consist of blood glucose meter, single use test strips, sterile lancets, lancing device and the control solutions.
The new device iHealth BG3 Smart Gluco-Monitoring System is based on an electrochemical biosensor technology (electrochemical) and the principle of capillary action. Capillary action at the end of the test strip draws the blood into the action chamber and the blood glucose result is displayed in 5 seconds. The control solution available is used to test the performance of the device. It uses the same technological characteristics for testing with its predicate device.
The appearance of iHealth BG3 meter is different from the predicate device. More over, the new device iHealth BG3 Smart Gluco-Monitoring System can not display the test results itself, it has to connect an iPhone or iPod touch to complete its function.

The iHealth BG3 Smart Gluco-Monitoring System's acceptance criteria are based on ISO 15197 for in vitro diagnostic test systems, specifically for blood-glucose monitoring systems used for self-testing in managing diabetes mellitus. The information provided does not contain specific numerical acceptance criteria (e.g., accuracy percentages or error grids) or detailed study results to demonstrate compliance with these criteria beyond a general statement that "Non-clinical test and the clinical test are done according to the above standard."

Therefore, I cannot populate a table of acceptance criteria and reported device performance with specific numbers.

Here's what can be extracted and inferred from the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample size used for the test set and the data provenance

• Sample Size: Not specified in the provided text.
• Data Provenance: The document does not specify the country of origin of the data or whether the study was retrospective or prospective. It only states that "Non-clinical test and the clinical test are done according to the [ISO 15197] standard."

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

• This information is not provided in the given text.

4. Adjudication method for the test set

• This information is not provided in the given text.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

• This device is a blood glucose monitoring system, not an AI-assisted diagnostic imaging or interpretation tool for human readers. Therefore, an MRMC comparative effectiveness study involving human readers and AI assistance is not applicable and was not performed.

6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done

• The iHealth BG3 Smart Gluco-Monitoring System is an in-vitro diagnostic device that provides a direct numerical measurement of glucose. Its performance is inherently standalone in the sense that the device itself generates the glucose reading. It connects to an iPhone or iPod touch to display results, but the measurement itself is performed by the device and test strip. The performance evaluation would measure the accuracy of these readings against a reference method.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

• For blood glucose monitoring systems complying with ISO 15197, the "ground truth" (or reference method) typically involves laboratory-grade glucose analyzers, often using methods like hexokinase or glucose oxidase reactions, which are considered highly accurate for quantitative glucose measurement. While not explicitly stated, it's highly probable that a laboratory reference method was used for comparison in the clinical and non-clinical tests.

8. The sample size for the training set

• This information is not provided in the given text. Blood glucose meters do not typically have "training sets" in the same way machine learning algorithms do. Instead, their development involves calibration and characterization using a range of known glucose concentrations.

9. How the ground truth for the training set was established

• As mentioned above, the concept of a "training set" with ground truth in the context of machine learning isn't directly applicable here. The development and calibration of blood glucose meters involve rigorous testing against laboratory reference methods across the device's intended measurement range and various interfering substances to ensure accuracy.

Ask a specific question about this device

The AG-6081 Single Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertip, palm, forearm, upper arm, calf and thigh. The AG-6081 Single Blood Glucose Monitoring System is to be used by a single person and should not be shared.

The AG-6081 Single Blood Glucose Monitoring System is intended for self testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The AG-6081 Single Blood Glucose Monitoring System should not be used for the diagnosis of or screening for diabetes, nor for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly).

The AGS-1100 Single Blood Glucose Test Strips are for use with the AG-6081 Single Blood Glucose Meter to quantitatively measure glucose in fresh capillary whole blood samples drawn from the fingertips, palm, forearm, upper arm, calf and thigh.

The AGS-1100 Glucose Controls are intended for in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of the AG-6081 Single meters and AGS-1100 Single test strips.

The AG-6951 Single Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertip, palm, forearm, upper arm, calf and thigh. The AG-6951 Single Blood Glucose Monitoring System is to be used by a single person and should not be shared.

The AG-6951 Single Blood Glucose Monitoring System is intended for self testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The AG-6951 Single Blood Glucose Monitoring System should not be used for the diagnosis of or screening for diabetes, nor for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly).

The AGS-1100 Single Blood Glucose Test Strips are for use with the AG-6951 Single Blood Glucose Meter to quantitatively measure glucose in fresh capillary whole blood samples drawn from the fingertips, palm, forearm, upper arm, calf and thigh.

The AGS-1100 Glucose Controls are intended for in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of the AG-6951 Single meters and AGS-1100 Single test strips.

This system contains a speaking function that provides audible test results for users with impaired vision. The audible function does not provide complete instructions for all functions of the meter or for performing a glucose test.

The AG-6081 MULTI Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertip, palm, forearm, upper arm, calf and thigh. The AG-6081 MULTI Blood Glucose Monitoring System is intended for testing outside the body (in vitro diagnostic use) and is intended for multiple-patient use in professional healthcare settings as an aid to monitor the effectiveness of a diabetes control program.

The AG-6081 MULTI Blood Glucose Monitoring System should not be used for the diagnosis of or screening for diabetes, nor for neonatal use. Alternative site testing such as the palm, forearm, upper arm, calf and thigh should be done only during steady - state times (when glucose is not changing rapidly).

The AGS-1100 MULTI Blood Glucose Test Strips are for use with the AG-6081 MULTI Blood Glucose Meter to quantitatively measure glucose in fresh capillary whole blood samples drawn from the fingertips, palm, forearm, upper arm, calf and thigh.

The AGS-1100 Glucose Controls are intended for in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of the AG-6081 MULTI meters and AGS-1100 MULTI test strips.

The AG-6951 MULTI Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertip, palm, forearm, upper arm, calf and thigh. The AG-6951 MULTI Blood Glucose Monitoring System is intended for testing outside the body (in vitro diagnostic use) and is intended for multiple-patient use in professional healthcare settings as an aid to monitor the effectiveness of a diabetes control program.

The AG-6951 MULTI Blood Glucose Monitoring System should not be used for the diagnosis of or screening for diabetes, nor for neonatal use. Alternative site testing such as the palm, forearm, upper arm, calf and thigh should be done only during steady - state times (when glucose is not changing rapidly).

The AGS-1100 MULTI Blood Glucose Test Strips are for use with the AG-6951 MULTI Blood Glucose Meter to quantitatively measure glucose in fresh capillary whole blood samples drawn from the fingertips, palm, forearm, upper arm, calf and thigh.

The AGS-1100 Glucose Controls are intended for in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of the AG-6951 MULTI meters and AGS-1100 MULTI test strips.

This system contains a speaking function that provides audible test results for users with impaired vision. The audible function does not provide complete instructions for all functions of the meter or for performing a glucose test.

AG-6081 and AG-6951 Single Blood Glucose Monitoring System (BGMS) consist of blood glucose meter, single use test strips, sterile lancets, lancing device and the control solutions.

While AG-6081 and AG-6951 MULTI Blood Glucose Monitoring System (BGMS) consist of blood glucose meter, MULT! use test strips, Auto-disabling Lancing device and the control solutions.

The four blood Glucose Monitoring system AG-6081 Single, AG-6951 Single, AG-6081 MULTI and AG-6951 MULTI are all based on an electrochemical biosensor technology (electrochemical) and the principle of capillary action. Capillary action at the end of the test strip draws the blood into the action chamber and the blood glucose result is displayed in 5 seconds. The control solution available is used to test the performance of the device. All of them use the same technological characteristics for testing with their predicate device. Only the appearance is different from their predicate device, and the new devices can test the blood glucose at the alternative site: the palm, the forearm, the upper arm, the calf and the thigh.

More over, AG-6951 Single and AG-6951 MULTI Blood Glucose Monitoring Systems have a voice function, which is also different from their predicate device.

This document describes the AG-6081 Single, AG-6081 MULTI, AG-6951 Single, and AG-6951 MULTI Blood Glucose Monitoring Systems (BGMS). These devices are intended for the quantitative measurement of glucose in fresh capillary whole blood samples. The document focuses on comparing the new devices to a predicate device (AG-606 Blood Glucose Monitoring System, K073030) and claims conformity to relevant standards, but provides very limited details about the specific studies.

Here's an attempt to answer your questions based on the provided text, while acknowledging the severe limitations in the available information:

1. Table of Acceptance Criteria and Reported Device Performance

The document states that the devices conform to the following standards:

• ISO 15197: In vitro diagnostic test systems- Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus.
• FDA Draft Guidance Document-Total Product Life Cycle for Portable Invasive Blood Glucose Monitoring Systems: October 24, 2006
• CLSI/NCCLS Guideline, EP07-A2 Interference Testing in Clinical Chemistry; Approved Guideline-Second edition

However, the specific "acceptance criteria" (e.g., accuracy percentages, bias limits) from these standards and the "reported device performance" in relation to these criteria are not explicitly provided in the text. The document only states that "the test in this submission provides demonstration that these small differences do not raise any new questions of safety and effectiveness," implying that the devices met the performance requirements referenced in these standards without detailing the actual results.

2. Sample Size Used for the Test Set and Data Provenance

This information is not provided in the document. There is no mention of the number of samples, participants, or the type of study (retrospective or prospective) used for performance evaluation. The country of origin of the data is also not specified, though the submitter is based in Tianjin, China.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications

This information is not provided in the document. The text does not detail any expert involvement in establishing ground truth.

4. Adjudication Method for the Test Set

This information is not provided in the document.

5. Multi-Reader, Multi-Case (MRMC) Comparative Effectiveness Study

A multi-reader, multi-case comparative effectiveness study with human readers and AI assistance is not applicable to this type of medical device (blood glucose monitoring system). These devices are standalone measurement tools and do not involve human interpretation of complex images or data that AI would assist with in the usual sense of an MRMC study.

6. Standalone Performance Study

Based on the claim of conformity to ISO 15197 and FDA guidance for blood glucose monitoring systems, a standalone performance study would have been conducted. ISO 15197 specifies accuracy requirements for glucose meters, which are assessed by comparing meter readings to a reference method (e.g., laboratory analyzer). While the document states "the test in this submission provides demonstration that these small differences do not raise any new questions of safety and effectiveness," the detailed results of such a standalone study are not explicitly presented.

7. Type of Ground Truth Used

For blood glucose monitoring systems, the ground truth is typically established using a laboratory reference method (e.g., hexokinase method on a clinical chemistry analyzer) to measure blood glucose concentrations. The device's readings are then compared against these highly accurate reference values. This is implied by the nature of such devices and the standards cited, but not directly stated in the provided text.

8. Sample Size for the Training Set

This information is not applicable as blood glucose monitoring systems of this type (electrochemical biosensors) are not typically "trained" in the machine learning sense. Their performance is inherent to their design and manufacturing, rather than learned from a dataset.

9. How the Ground Truth for the Training Set Was Established

This information is not applicable for the reasons stated above.

Ask a specific question about this device

The FORA G90 / U-Right TD-4234 Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the following alternative sites: the palm, the forearm, the upper-arm, the calf and the thigh. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus, nor is it intended for use on newborns.

The alternative site testing in this system can be used only during steady-state blood glucose conditions.

Not Found

I am sorry, but the provided text does not contain the acceptance criteria or a study proving the device meets those criteria. The document is an FDA 510(k) clearance letter for the FORA G90 / U-Right TD-4234 Blood Glucose Monitoring System, which states that the device is substantially equivalent to a legally marketed predicate device.

The document discusses:

• The FDA's review of the premarket notification.
• The device's classification and regulation details.
• General controls provisions and other regulatory requirements.
• The instructions for use and indications for the device.

It does not include any information about:

• Specific acceptance criteria (e.g., accuracy percentages, limits of agreement).
• A study's design, results, or comparison to acceptance criteria.
• Sample sizes for test or training sets.
• Data provenance.
• Details about establishing ground truth.
• Information on MRMC studies or standalone algorithm performance.

Therefore, I cannot fulfill your request based on the provided text.

Ask a specific question about this device

The FREEDOM Blood Glucose Monitoring System is used for the quantitative measurement of glucose level in whole blood as an aid in monitoring the effectiveness of diabetes management in the home and in clinical settings. The FREEDOM Blood Glucose Monitoring System is for testing outside the body (in vitro diagnostic use only). Testing sites include the traditional fingertip testing along with alternate site testing on the arm, palm, thigh and calf.

The FREEDOM Blood Glucose Monitoring System is an in vitro diagnostic device designed for measuring the concentration of glucose in whole blood, which is used with the FREEDOM Test Strips.

The test principle is:

This device is an in vitro diagnostic product intended for the measurement of glucose concentration in human blood. The principle of the test relies upon a specific type of glucose in the blood sample, the dehydrogenase glucose that reacts to electrodes in the test strip. The test strip employs an electrochemical signal generating an electrical current that will stimulate a chemical reaction. This reaction is measured by the Meter and displayed as your blood glucose result.

This is an in vitro diagnostic device, not an AI/ML device, so many of the requested categories (e.g., number of experts, adjudication method, MRMC study, sample size for training set) are not applicable. The information provided focuses on the device's accuracy against established references, which is typical for this type of device.

Acceptance Criteria and Device Performance

The provided 510(k) summary does not explicitly state acceptance criteria in a quantitative table format nor reported device performance in a similar table. However, based on the nature of blood glucose monitoring systems and the reference to substantial equivalence to predicate devices, the acceptance criteria would implicitly involve the device demonstrating accuracy and precision comparable to or better than the predicate devices and meeting relevant ISO standards for blood glucose monitoring.

From the information provided, it states that the device measures "the concentration of glucose in whole blood" and is "an aid in monitoring the effectiveness of diabetes management." The device claims "substantial equivalence to the LifeScan, Inc., OneTouch® Ultra®" and others. This implies that the performance (accuracy, precision) of the FREEDOM Blood Glucose Monitoring System must be within acceptable limits relative to these established predicate devices.

Implicit Acceptance Criteria (based on common standards for IVD blood glucose meters) & Reported Device Performance:

Note: The 510(k) summary itself does not contain a detailed performance study report with specific accuracy or precision statistics for the FREEDOM Blood Glucose Monitoring System. The claim of "substantial equivalence" is the primary basis for market clearance, implying that the detailed performance data submitted to the FDA (but not included in this summary) demonstrated comparable performance to the predicate devices.

Study Details

1. Sample size used for the test set and the data provenance:
   The provided summary does not include specific details about the sample size used for performance testing or the provenance of the data (e.g., country of origin, retrospective/prospective). For an in vitro diagnostic device like a blood glucose meter, the test set would typically involve human blood samples across a range of glucose concentrations, tested against a reference method.

2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
   This is not applicable for a blood glucose monitoring system. The "ground truth" for blood glucose measurements is established by a highly accurate and precise laboratory reference method (e.g., an enzymatic hexokinase method on a laboratory analyzer), not by human expert opinion.

3. Adjudication method (e.g. 2+1, 3+1, none) for the test set:
   This is not applicable. Adjudication methods involving multiple human readers are used for subjective interpretations (e.g., image analysis, clinical diagnoses). For quantitative measurements like blood glucose, the reference method provides a definitive quantitative value, not a subjective interpretation requiring adjudication.

4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
   This is not applicable. An MRMC study is relevant for AI/ML devices that assist human readers in tasks like image interpretation. This device is a standalone in vitro diagnostic system for measuring a biochemical analyte. It does not involve human readers or AI assistance in interpretation.

5. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:
   Yes, this is implicitly a standalone performance study. The FREEDOM Blood Glucose Monitoring System is an "algorithm only" type of device in the sense that it performs a chemical and electrical measurement and provides a numerical output without human interpretation being part of its diagnostic function. Its performance is evaluated on its ability to accurately and precisely provide glucose concentrations compared to a reference standard. The product description emphasizes the electrochemical signal and its measurement by the meter, displayed as a blood glucose result.

6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
   The ground truth would be established by a highly accurate and precise laboratory-based reference method for glucose measurement, such as a hexokinase enzymatic method or isotope dilution-mass spectrometry (IDMS), performed on a clinical laboratory analyzer.

7. The sample size for the training set:
   This is not applicable in the context of traditional in vitro diagnostic devices like blood glucose meters. There is no "training set" in the machine learning sense. The device's electrochemical principles and algorithms are fixed during design and manufacturing. Performance is validated through testing on clinical samples, not by iterative training.

8. How the ground truth for the training set was established:
   As there is no training set in the AI/ML sense, this question is not applicable. The device's operating principles and internal calibration are established during its engineering design, and its accuracy is validated against a definitive laboratory reference standard.

Ask a specific question about this device